

## Dragon (RGMb) induces oxaliplatin resistance in colon cancer cells


**Supplementary Materials** 




**Supplementary Figure S1: Effect of Dragon on colony formation in the presence of oxaliplatin.** (A and B) Control and Dragon-overexpressing CMT93 cells were used to perform the colony formation assay in the presence of increasing doses of oxaliplatin and high glucose for 7 days (A). The colony numbers (B, left panel) and growth inhibition rate (B, right panel) are presented. Only the colonies with more than 50 cells were counted. (C and D) Control and Dragon-knockdown CMT93 cells were used to perform the colony formation assay in the presence of increasing doses of oxaliplatin and high glucose for 7 days (C). The colony numbers (D, left panel) and growth inhibition rate (D, right panel) are presented. Only the colonies with more than 50 cells were counted. \*P < 0.05 and \*\*P < 0.01.



**Supplementary Figure S2: Dragon overexpression inhibits oxaliplatin-induced apoptosis in HCT116 cells.** Glucosedeprived control and Dragon-overexpressing HCT116 cells were treated with increasing doses of oxaliplatin for 24 h before the cells were stained with PI. Cells apoptosis was analyzed by flow cytometry.



Supplementary Figure S3: Effect of Dragon overexpression on Smad1/5/8 phosphorylation in mouse xenograft tumors treated with oxaliplatin. Control (pLV) and Dragon-overexpressing (oeDra) xenograft tumors derived from oxaliplatin-treated CMT93 cells were collected for Western blotting to detect p-Smad1/5/8 and Smad1.



**Supplementary Figure S4: Jam-a is downregulated in Dragon-overexpressing xenograft tumors.** A cytokine antibody array was used to analyze the expression of 48 cytokines in oxaliplatin-treated xenograft tumors derived from control and Dragon-overexpressing cells. The heatmap of Hierarchical clustering analysis (A) and the volcano plot (B) showed that Jam-a was downregulated (P < 0.05) in Dragon-overexpressing xenograft tumors compared with controls treated with oxaliplatin.